AR124436A1 - DRY POWDER FORMULATION OF LIPOCALIN MUTEIN FOR THE TREATMENT OF ASTHMA - Google Patents
DRY POWDER FORMULATION OF LIPOCALIN MUTEIN FOR THE TREATMENT OF ASTHMAInfo
- Publication number
- AR124436A1 AR124436A1 ARP210103583A ARP210103583A AR124436A1 AR 124436 A1 AR124436 A1 AR 124436A1 AR P210103583 A ARP210103583 A AR P210103583A AR P210103583 A ARP210103583 A AR P210103583A AR 124436 A1 AR124436 A1 AR 124436A1
- Authority
- AR
- Argentina
- Prior art keywords
- lipocalin mutein
- dry powder
- powder formulation
- asthma
- fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al tratamiento del asma en un sujeto humano mediante la administración por inhalación oral de una formulación de polvo seco que comprende una cantidad terapéuticamente eficaz de una muteína de lipocalina anti-receptor a de IL-4 (IL-4Ra), o una variante o un fragmento de la misma, a dicho sujeto. La invención también se refiere a la formulación de polvo seco que comprende la muteína de lipocalina anti-receptor a de IL-4 (IL-4Ra), o una variante o un fragmento de la misma. Reivindicación 1: Un método para tratar el asma en un sujeto humano, en donde el método comprende administrar por inhalación una formulación de polvo seco que comprende una cantidad terapéuticamente eficaz de una muteína de lipocalina anti-receptor a de IL-4 (IL-4Ra) que comprende la secuencia de aminoácidos expuesta en SEQ ID Nº 1, o una variante o un fragmento de la misma, a dicho sujeto, en donde se administra una dosis nominal suministrada de aproximadamente 0.1 mg a aproximadamente 30 mg de dicha muteína de lipocalina, o variante o fragmento de la misma, a dicho sujeto por inhalación oral.The present invention relates to the treatment of asthma in a human subject by oral inhalation administration of a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor α lipocalin mutein (IL-4Ra), or a variant or fragment thereof, to said subject. The invention also relates to dry powder formulation comprising the IL-4 anti-receptor a lipocalin mutein (IL-4Ra), or a variant or fragment thereof. Claim 1: A method of treating asthma in a human subject, wherein the method comprises administering by inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor α lipocalin mutein (IL-4Ra ) comprising the amino acid sequence set forth in SEQ ID No. 1, or a variant or fragment thereof, to said subject, wherein a nominal delivered dose of about 0.1 mg to about 30 mg of said lipocalin mutein is administered, or variant or fragment thereof, to said subject by oral inhalation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127903P | 2020-12-18 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124436A1 true AR124436A1 (en) | 2023-03-29 |
Family
ID=79686778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103583A AR124436A1 (en) | 2020-12-18 | 2021-12-20 | DRY POWDER FORMULATION OF LIPOCALIN MUTEIN FOR THE TREATMENT OF ASTHMA |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4262845A1 (en) |
| JP (1) | JP2023553703A (en) |
| KR (1) | KR20230121785A (en) |
| CN (1) | CN116916945A (en) |
| AR (1) | AR124436A1 (en) |
| AU (1) | AU2021399151A1 (en) |
| CA (1) | CA3199479A1 (en) |
| CL (1) | CL2023001775A1 (en) |
| CO (1) | CO2023007904A2 (en) |
| CR (1) | CR20230265A (en) |
| IL (1) | IL303729A (en) |
| MX (1) | MX2023007174A (en) |
| PE (1) | PE20240799A1 (en) |
| TW (1) | TW202241490A (en) |
| WO (1) | WO2022129629A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US8313924B2 (en) | 2006-08-01 | 2012-11-20 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| HUE043835T2 (en) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Tear lipocalin muteins binding il-4 r alpha |
| CN109432402B (en) | 2011-12-13 | 2022-04-29 | 皮里斯制药有限公司 | Methods of preventing or treating certain disorders by inhibiting the binding of IL-4 and/or IL-13 to their respective receptors |
| CA3127973A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| MA55490A (en) | 2019-03-29 | 2022-02-09 | Astrazeneca Ab | LIPOCALIN MUTEIN FOR THE TREATMENT OF ASTHMA |
-
2021
- 2021-12-20 IL IL303729A patent/IL303729A/en unknown
- 2021-12-20 MX MX2023007174A patent/MX2023007174A/en unknown
- 2021-12-20 PE PE2023001901A patent/PE20240799A1/en unknown
- 2021-12-20 CR CR20230265A patent/CR20230265A/en unknown
- 2021-12-20 CN CN202180085274.3A patent/CN116916945A/en active Pending
- 2021-12-20 TW TW110147707A patent/TW202241490A/en unknown
- 2021-12-20 JP JP2023536889A patent/JP2023553703A/en active Pending
- 2021-12-20 AU AU2021399151A patent/AU2021399151A1/en not_active Abandoned
- 2021-12-20 AR ARP210103583A patent/AR124436A1/en not_active Application Discontinuation
- 2021-12-20 KR KR1020237023191A patent/KR20230121785A/en active Pending
- 2021-12-20 EP EP21844230.9A patent/EP4262845A1/en not_active Withdrawn
- 2021-12-20 CA CA3199479A patent/CA3199479A1/en active Pending
- 2021-12-20 WO PCT/EP2021/086730 patent/WO2022129629A1/en not_active Ceased
-
2023
- 2023-06-15 CL CL2023001775A patent/CL2023001775A1/en unknown
- 2023-06-16 CO CONC2023/0007904A patent/CO2023007904A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230121785A (en) | 2023-08-21 |
| AU2021399151A9 (en) | 2025-03-06 |
| CR20230265A (en) | 2023-09-29 |
| CA3199479A1 (en) | 2022-06-23 |
| IL303729A (en) | 2023-08-01 |
| PE20240799A1 (en) | 2024-04-18 |
| MX2023007174A (en) | 2023-09-08 |
| TW202241490A (en) | 2022-11-01 |
| CO2023007904A2 (en) | 2023-10-30 |
| CN116916945A (en) | 2023-10-20 |
| CL2023001775A1 (en) | 2024-01-19 |
| JP2023553703A (en) | 2023-12-25 |
| WO2022129629A1 (en) | 2022-06-23 |
| AU2021399151A1 (en) | 2023-07-27 |
| EP4262845A1 (en) | 2023-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weisler et al. | Comparison of bupropion and trazodone for the treatment of major depression | |
| JP2020512363A5 (en) | ||
| EP3551187B1 (en) | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol | |
| CL2024003601A1 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases. | |
| CL2024003616A1 (en) | Oral pharmaceutical composition and use for the therapy of progressive fibrosing interstitial lung diseases. | |
| ES2647584T3 (en) | Method for producing vaccines comprising irradiation of microorganisms in a composition comprising amino acids and manganese orthophosphate | |
| AR124436A1 (en) | DRY POWDER FORMULATION OF LIPOCALIN MUTEIN FOR THE TREATMENT OF ASTHMA | |
| Cortes et al. | Chemotherapy for head and neck cancer relapsing after radiotherapy | |
| US12478618B1 (en) | Use of glutamate 2B receptor antagonists and sigma receptor agonists as antitussives | |
| JP7369523B2 (en) | Treatment of moderate to severe influenza | |
| Manuel et al. | Asthma and dental erosion | |
| WO2025167739A1 (en) | Use of compound in preparing drug for preventing and/or treating mountain sickness | |
| US11701383B2 (en) | Composition and therapy for treatment of gag reflexes | |
| MX2024008330A (en) | Obicetrapib and sglt2 inhibitor combination | |
| WO2022063320A1 (en) | Composition for inhibiting respiratory virus and respiratory virus prevention and treatment method | |
| CN101657210A (en) | Method of treating or preventing tissue deterioration, injury or damage due to disease of mucosa | |
| WO2021221741A1 (en) | Nutritional composition comprising carnitine and method for treating or preventing an infection in a mammal | |
| JP7155116B2 (en) | Pharmaceutical compositions and methods for treating female sexual dysfunction | |
| WO2014096301A1 (en) | ß2-ADRENOCEPTOR AGONIST FOR IMPROVEMENT OF EXERCISE TOLERANCE | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| Elkady et al. | Efficacy of Melatonin Oral Gel in Reducing Oral Mucositis in Patients with Head and Neck Cancer under Chemoradiation | |
| RU2736046C1 (en) | Method of treating chronic pharyngitis | |
| JP2012102085A (en) | Pharmaceutical composition containing pde5 inhibitor | |
| Rush | Treatment of inflammatory airway disease: aerosol delivery devices and medications | |
| Petruzzi | Tozinameran: Oral erythema multiforme: 4 case reports |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |